A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

NCT06688435 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Myasthenia Gravis

Interventions

BIOLOGICAL: SYS6020 injection

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.